Revolution Medicines, Inc. Common Stock
RVMD
$205.11
+0.66%
Revolution Medicines, Inc. is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers, built around a proprietary pipeline of RAS(ON) inhibitors designed to bind directly to RAS variants as monotherapy or in combination with other agents. The company occupies a differentiated position in the competitive RAS-targeting landscape, leveraging structure-based drug discovery capabilities and chemical biology expertise to create small molecules tailored to unconventional binding sites that have historically been considered undruggable. The current investor narrative is dominated by the rapid FDA approval of Rasonque (daraxonrasib) following a Phase 3 pancreatic cancer trial that doubled survival versus chemotherapy, a landmark result that has transformed RVMD from a speculative clinical-stage story into a near-commercial oncology platform. This narrative is amplified by a concurrent $2.2 billion upsized public offering that de-risked the balance sheet, analyst projections of $11.5 billion in peak sales, and a stock that has appreciated more than 5x, leaving investors to debate whether the approval and pipeline optionality are fully priced in or whether the commercial ramp represents a second leg of upside.…
RVMD
Revolution Medicines, Inc. Common Stock
$205.11
Related headlines
Investment Opinion: Should I buy RVMD Today?
The synthesized recommendation is a Hold with a bullish bias, reflecting the transformative potential of daraxonrasib balanced against a valuation that already prices in substantial success. The analyst consensus is a strong buy with a mean rating of 1.29 and an average target price of $251.21, implying 23.3% upside, but the stock's 5x run and premium multiples warrant caution. The core thesis is that RVMD offers a compelling long-term opportunity in RAS-targeted oncology, but near-term upside is limited without evidence of rapid commercial adoption.
Supporting evidence includes the FDA approval of daraxonrasib, which doubled survival in pancreatic cancer, and a fortress balance sheet with a current ratio of 7.14 and debt-to-equity of 0.097 following the $2.2 billion raise. Analyst projections of $11.5 billion in peak sales imply a market cap-to-peak-sales multiple of 3.9x, which is rich but not unprecedented for a first-in-class asset. However, the company is pre-revenue with a Q1 2026 net loss of -$453.8 million and TTM free cash flow of -$1.07 billion, and the price-to-book ratio of 9.28 is near the high end of its historical range. The implied upside to the average target is 23.3%, but the wide target spread ($179-$320) signals uncertainty.
The biggest risks that could invalidate the thesis are slower-than-expected commercial uptake, competitive threats in the RAS space, and dilution from future capital raises. The rating would upgrade to Buy if the stock pulls back to the $180-$190 support zone or if launch metrics show accelerating revenue, and it would downgrade to Sell if revenue growth stalls or if R&D spending continues to outpace cash reserves. Relative to its history and peers, RVMD appears overvalued on a price-to-book basis, but the premium may be justified if peak sales estimates are met; thus, the stock is fairly valued to slightly overvalued at current levels.
Sign up to view all
RVMD 12-Month Price Forecast
RVMD presents a compelling long-term opportunity in RAS-targeted oncology, but the stock's 5x run has priced in much of the near-term upside, warranting a neutral stance. The FDA approval of daraxonrasib is transformative, and the $2.2 billion raise provides a strong financial foundation, yet the company remains pre-revenue with significant cash burn. Analyst sentiment is overwhelmingly bullish, but the wide target spread and high beta (1.406) signal substantial uncertainty. I would upgrade to bullish if commercial launch metrics show accelerating revenue and pipeline expansion succeeds, or downgrade to bearish if launch disappoints or competitive threats intensify.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Revolution Medicines, Inc. Common Stock's 12-month outlook, with a consensus price target around $251.21 and implied upside of +22.5% versus the current price.
Average Target
$251.21
0 analysts
Implied Upside
+22.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$179 - $320
Analyst target range
RVMD is covered by 20 analysts, with a consensus recommendation of "strong_buy" and a recommendation mean of 1.29 (where 1.0 is a strong buy and 5.0 is a strong sell), indicating overwhelming bullish sentiment. The average target price is $251.21, which implies approximately 23.3% upside from the current price of $203.77. The consensus is firmly bullish, supported by recent reiterations from Guggenheim (Buy), HC Wainwright (Buy), Mizuho (Outperform), Wedbush (Outperform), Truist (Buy), Needham (Buy), Evercore ISI (Outperform), RBC Capital (Outperform), and Oppenheimer (Outperform), with no downgrades or sell ratings observed in the institutional ratings data. This uniform bullishness reflects the transformative nature of the daraxonrasib approval and the perceived blockbuster potential of the RAS(ON) platform.
The target price range spans from a low of $179.00 to a high of $320.00, a spread of $141.00, or approximately 79% of the low target, which signals meaningful uncertainty about the commercial trajectory and pipeline outcomes. The high target of $320.00 implies roughly 57% upside and likely assumes rapid commercial adoption of daraxonrasib, successful expansion into additional RAS-mutant indications, and multiple expansion as the company transitions to a commercial-stage entity. The low target of $179.00 implies approximately 12.2% downside from the current price and likely prices in slower-than-expected launch uptake, competitive pressures in the pancreatic cancer space, or dilution from future capital raises. The wide spread between the high and low targets, combined with the stock's beta of 1.406 and short ratio of 5.32, suggests that investors should expect continued volatility as the market digests commercial execution and pipeline data; the strong buy consensus provides a supportive backdrop, but the stock's 5x run means much of the good news may already be reflected in the price.
Drowning in data?
Find the real signal!
Bulls vs Bears: RVMD Investment Factors
The bull case rests on the transformative FDA approval of daraxonrasib, a strong buy consensus with 23% upside to the average target, a fortress balance sheet with $2.2 billion raised, and blockbuster peak sales potential of $11.5 billion. The bear case highlights extreme valuation (9.28x book, 3.9x peak sales), deep cash burn (-$1.07 billion TTM FCF), a wide analyst target spread, and high volatility (beta 1.406) with the stock near its 52-week high. Currently, the bull evidence is stronger due to the de-risked regulatory path and overwhelming analyst support, but the margin of safety is thin. The single most important tension is whether the commercial launch of daraxonrasib can ramp fast enough to justify the premium valuation before cash reserves dwindle or competition emerges. If launch metrics exceed expectations, the stock could re-rate higher; if they disappoint, the downside could be severe given the priced-in optimism.
Bullish
- FDA Approval Validates RAS(ON) Platform: Rasonque (daraxonrasib) received FDA approval for pancreatic cancer after a Phase 3 trial doubled survival versus chemotherapy, a landmark result that de-risks the entire RAS(ON) pipeline. This approval transforms RVMD from a speculative clinical-stage story into a near-commercial oncology platform with a first-in-class asset.
- Analyst Consensus Strong Buy with 23% Upside: 20 analysts rate RVMD a strong buy with a mean recommendation of 1.29 and an average target price of $251.21, implying 23.3% upside from the current $203.77. The high target of $320.00 suggests 57% upside, reflecting confidence in rapid commercial adoption.
- Fortress Balance Sheet Post $2.2B Raise: The April 2026 $2.2 billion upsized public offering boosted cash and short-term investments, resulting in a current ratio of 7.14 and a debt-to-equity ratio of just 0.097. This liquidity fully funds the commercial launch and pipeline expansion, eliminating near-term financing risk.
- Massive Momentum and Relative Strength: RVMD is up 340.68% over the past year and 157.87% year-to-date, crushing the S&P 500's 16.22% and 12.08% gains. The 1-year relative strength of 324.46 versus SPY confirms it is one of the market's strongest momentum vehicles, attracting institutional inflows.
Bearish
- Extreme Valuation Leaves No Margin of Safety: The price-to-book ratio of 9.28 is near the upper end of its historical range (2.16x to 12.84x), and the market cap-to-peak-sales multiple of 3.9x is rich for a pre-revenue company. The stock's 5x run means much of the good news is already priced in, leaving limited room for error.
- Deeply Negative Profitability and Cash Burn: Q1 2026 net income was -$453.8 million with an EBITDA of -$437.1 million, and trailing twelve-month free cash flow was -$1.07 billion. R&D expenses surged 67.2% year-over-year to $344.0 million, and the net loss widened sequentially from -$213.4 million in Q1 2025, highlighting the heavy cash requirements.
- Wide Analyst Target Spread Signals Uncertainty: The target price range spans from $179.00 to $320.00, a spread of $141.00 or 79% of the low target. This wide dispersion reflects meaningful uncertainty about commercial execution, competitive pressures, and pipeline outcomes, with the low target implying 12.2% downside.
- High Volatility and Short Interest: With a beta of 1.406, RVMD is 41% more volatile than the market, and a 24.95% maximum drawdown over the past year underscores the risk. The short ratio of 5.32 indicates active short selling, and light volume (1.38 million shares on the most recent session) could amplify downside moves.
RVMD Technical Analysis
RVMD is in a powerful, sustained uptrend, with the stock up 340.68% over the past year and 157.87% year-to-date, dramatically outperforming the S&P 500's 16.22% and 12.08% respective gains. At a current price of $203.77, the stock is trading at approximately 88.6% of its 52-week range (low of $42.18, high of $224.31), positioning it near the upper end of its annual band. This proximity to highs signals strong momentum and institutional accumulation, but also raises the risk of profit-taking and mean reversion, particularly given the stock's 24.95% maximum drawdown over the period, which underscores the volatility inherent in this name. The 1-year relative strength of 324.46 versus SPY confirms that RVMD has been one of the market's most dominant momentum vehicles, though such extreme outperformance often precedes periods of consolidation or correction.
Short-term momentum has decelerated sharply relative to the longer-term trend, with the stock down 0.73% over the past month versus a 32.43% gain over three months and a 114.81% gain over six months. This divergence between a flat-to-negative 1-month return and a strongly positive 1-year return suggests the stock is digesting its massive run rather than reversing trend, a classic consolidation pattern following a parabolic advance. The 1-month relative strength versus SPY is a modest 0.33, indicating RVMD is essentially moving in line with the market over the near term after a period of extreme outperformance. The short ratio of 5.32 indicates that short sellers have been active, and with only 1.38 million shares traded on the most recent session, volume appears light relative to the stock's market cap, which could amplify volatility on any catalyst.
Key technical support sits at the 52-week low of $42.18, though a more relevant near-term support zone would be the $180-$190 area where the stock consolidated in July 2026 before breaking higher. Resistance is defined by the 52-week high of $224.31, and a breakout above this level would signal a continuation of the primary uptrend and likely attract momentum-driven inflows. Conversely, a breakdown below $180 would suggest a deeper correction toward the $150-$160 region, which served as a launchpad in June 2026. With a beta of 1.406, RVMD is approximately 41% more volatile than the broader market, meaning position sizing should account for amplified drawdowns; a 10% market decline could translate to a roughly 14% decline in RVMD, all else equal.
Beta
1.41
1.41x market volatility
Max Drawdown
-24.9%
Largest decline past year
52-Week Range
$42-$224
Price range past year
Annual Return
+340.6%
Cumulative gain past year
| Period | RVMD Return | S&P 500 |
|---|---|---|
| 1m | +0.7% | -2.0% |
| 3m | +31.0% | +1.4% |
| 6m | +109.1% | +15.0% |
| 1y | +340.6% | +15.7% |
| ytd | +159.6% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RVMD Fundamental Analysis
Revolution Medicines is a pre-revenue clinical-stage biotechnology company, with Q1 2026 revenue of $0 and no product sales recorded as of the March 31, 2026 quarter. The only revenue line item in the data is $7.014 million in collaboration revenue, which is immaterial relative to the company's $44.6 billion market cap and reflects the early-stage nature of its commercial operations. The absence of a revenue trajectory makes traditional growth analysis inapplicable; instead, the investment case rests entirely on the clinical and regulatory progress of the RAS(ON) inhibitor pipeline, particularly daraxonrasib, which received FDA approval for pancreatic cancer. The multi-quarter trend shows no revenue acceleration or deceleration because there is no commercial revenue base yet, and the company's valuation is therefore a function of future peak sales estimates, which analysts peg at $11.5 billion.
Profitability remains deeply negative, with Q1 2026 net income of -$453.8 million and an EBITDA of -$437.1 million, reflecting the heavy research and development spending required to advance a broad oncology pipeline. Research and development expenses were $344.0 million in Q1 2026, up from $205.7 million in Q1 2025, a 67.2% year-over-year increase that underscores the accelerating investment in clinical trials and pre-commercialization activities. Gross margin is not meaningful at this stage, as the company has no product revenue and reported a gross profit of -$4.5 million, which is essentially a cost of revenue artifact. The net loss has widened sequentially from -$213.4 million in Q1 2025 to -$453.8 million in Q1 2026, and while this is expected for a company scaling toward commercialization, it highlights the significant cash burn required to bring a pipeline to market.
The balance sheet is exceptionally strong, with a current ratio of 7.14 and a debt-to-equity ratio of just 0.097, reflecting the $2.2 billion capital raise completed in April 2026 and a conservative capital structure. Free cash flow for the trailing twelve months was -$1.07 billion, and Q1 2026 free cash flow was -$355.7 million, indicating that the company is burning cash at a significant rate but has ample liquidity to fund operations for the foreseeable future. Cash at the end of Q1 2026 was $440.9 million, up from $383.7 million at the beginning of the period, largely due to $239.0 million in common stock issued during the quarter. Return on equity is deeply negative at -69.35%, and return on assets is -30.12%, which is typical for a pre-revenue biotech but underscores that the company is not yet generating returns on its invested capital. The key fundamental question is whether the commercial launch of daraxonrasib can generate sufficient revenue to offset the current burn rate before the company needs to raise additional capital.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-1.1B
Last 12 Months
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RVMD Overvalued?
Because Revolution Medicines reported negative net income of -$453.8 million in Q1 2026 and a trailing EPS of -$0.075, the PE ratio is not a meaningful valuation metric; the trailing PE of -13.39 and forward PE of -34.23 are negative and therefore uninformative. Similarly, the PS ratio is reported as 0, and with no revenue, EV/Sales and EV/EBITDA are also negative or undefined (EV/EBITDA of -13.68). The most relevant valuation framework for RVMD is therefore a pipeline-based, risk-adjusted net present value approach or a comparison of market cap to projected peak sales, where the current $44.6 billion market cap against analyst peak sales estimates of $11.5 billion implies a market cap-to-peak-sales multiple of approximately 3.9x, which is rich but not unprecedented for a first-in-class oncology asset with blockbuster potential.
Peer comparison is challenging because RVMD's valuation multiples are not comparable to profitable biotechnology peers; however, against the broader biotechnology sector, where many commercial-stage companies trade at 4-8x forward sales, RVMD's lack of revenue makes direct multiple comparison impossible. The price-to-book ratio of 9.28 is elevated relative to the sector median, reflecting the market's willingness to pay a premium for the company's intellectual property and pipeline rather than its tangible book value. This premium is justified only if daraxonrasib and the broader RAS(ON) portfolio achieve the $11.5 billion peak sales estimate, which would represent a significant share of the pancreatic cancer and broader RAS-mutant tumor markets. The stock's 340.68% one-year return and 157.87% YTD gain suggest the market has already priced in substantial commercial success, leaving limited margin of safety if clinical or commercial execution disappoints.
Historically, RVMD's price-to-book ratio has ranged from approximately 2.16x in Q1 2023 to 12.84x in Q1 2026, placing the current 9.28x near the upper end of its historical band. The trailing PE has been negative throughout the company's history, so no historical PE range is meaningful. The price-to-free-cash-flow ratio of -16.87 and price-to-operating-cash-flow ratio of -54.40 reflect the company's cash burn and are not useful valuation signals. The current valuation is therefore at the high end of its own historical range on a price-to-book basis, which suggests the market is pricing in optimistic expectations for the pipeline; this could represent a value opportunity if the commercial launch exceeds expectations, or a significant downside risk if the launch trajectory or pipeline readouts disappoint.
PE
-13.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-13.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant for RVMD, given its pre-revenue status and heavy cash burn. In Q1 2026, the company reported a net loss of -$453.8 million and negative EBITDA of -$437.1 million, with R&D expenses up 67.2% year-over-year to $344.0 million. Trailing twelve-month free cash flow was -$1.07 billion, and although the $2.2 billion capital raise in April 2026 bolstered the balance sheet (current ratio 7.14, debt-to-equity 0.097), the company must rapidly commercialize daraxonrasib to offset ongoing losses. The absence of product revenue and reliance on a single asset for near-term growth concentrates risk; any launch delay or clinical setback could force additional dilutive financing.
Market and competitive risks are elevated due to RVMD's premium valuation and high beta. The stock trades at a price-to-book ratio of 9.28, near the top of its historical range (2.16x to 12.84x), and a market cap-to-peak-sales multiple of 3.9x, leaving little room for disappointment. With a beta of 1.406, RVMD is 41% more volatile than the broader market, meaning a 10% market decline could translate to a roughly 14% drop. Competitive threats in the RAS-targeting space are intensifying, and the recent Merck-Terns acquisition highlights big pharma's interest in oncology, which could lead to rival therapies. Additionally, the stock's 340.68% one-year return and 157.87% YTD gain suggest momentum-driven positioning that could reverse sharply on any negative news.
The worst-case scenario involves a combination of slower-than-expected commercial uptake of daraxonrasib, competitive pressure from new entrants, and a broad biotech selloff. In this scenario, the stock could retest its 52-week low of $42.18, representing a 79.3% decline from the current price of $203.77. Even a less severe bear case, aligned with the analyst low target of $179.00, implies a 12.2% downside. Given the 24.95% maximum drawdown over the past year, investors should be prepared for significant volatility; a realistic adverse scenario could see the stock fall 30-40% to the $120-$140 range if launch metrics disappoint or pipeline readouts fail.
FAQ
The key risks for RVMD include financial, competitive, macro, and company-specific factors. Financially, the company is burning cash at a significant rate, with TTM free cash flow of -$1.07 billion and a Q1 2026 net loss of -$453.8 million, though the $2.2 billion raise provides a cushion. Competitively, the RAS-targeting space is intensifying, and rivals could develop superior therapies. Macro risks include a high beta of 1.406, making the stock 41% more volatile than the market, and sensitivity to biotech sector rotation. Company-specific risks center on commercial execution of daraxonrasib; if launch metrics disappoint, the stock could fall to the analyst low target of $179.00 or lower. The most severe risk is a complete pipeline failure, which could drive the stock toward its 52-week low of $42.18.
The 12-month forecast for RVMD includes three scenarios: a bull case with 30% probability targeting $280-$320, a base case with 50% probability targeting $230-$270, and a bear case with 20% probability targeting $150-$180. The base case is most likely, assuming a steady commercial launch that meets analyst average revenue estimates of $6.8 billion and a stock price near the average target of $251.21. The bull case hinges on rapid adoption and pipeline expansion, while the bear case assumes slower uptake or competitive threats. The key assumption behind the base case is that daraxonrasib launch metrics are in line with expectations, with no major negative surprises.
RVMD appears overvalued on traditional metrics, with a price-to-book ratio of 9.28 near the high end of its historical range (2.16x to 12.84x) and a market cap-to-peak-sales multiple of 3.9x. The company has no revenue, so PE and PS ratios are not meaningful, but the negative trailing PE of -13.39 and forward PE of -34.23 reflect deep losses. The market is pricing in optimistic expectations for daraxonrasib, with peak sales estimates of $11.5 billion. If those estimates are met, the valuation could be justified, but any disappointment could lead to significant multiple compression. Compared to profitable biotech peers trading at 4-8x forward sales, RVMD's premium is steep, implying the market expects flawless execution.
RVMD is a good buy for aggressive growth investors who can tolerate high volatility and a long investment horizon. The stock has 23.3% upside to the analyst average target of $251.21, supported by the FDA approval of daraxonrasib and a strong buy consensus from 20 analysts. However, the valuation is rich at 9.28x book and 3.9x peak sales, and the company is pre-revenue with a Q1 2026 net loss of -$453.8 million. The biggest downside risk is a retest of the 52-week low of $42.18, representing a 79% decline, though a more realistic bear case targets $179.00. For those with a high risk tolerance and a 3-5 year horizon, RVMD offers exposure to a potentially transformative oncology platform.
RVMD is more suitable for long-term investment given its clinical-stage nature, high volatility (beta 1.406), and lack of dividend (yield 0%). The company is transitioning to commercial-stage, but earnings visibility remains low, and the stock has experienced a 24.95% maximum drawdown in the past year. Short-term trading is risky due to binary events like clinical readouts and launch metrics, which can cause sharp price swings. A minimum holding period of 3-5 years is recommended to allow the commercial ramp of daraxonrasib to materialize and for pipeline expansion to drive value. Investors should size positions accordingly, as a 10% market decline could translate to a 14% drop in RVMD.
